Introduction {#sec1}
============

Ligand-based virtual screening (LBVS) is underpinned by the hypothesis that compounds with similar chemical structures tend to have similar biological activities.^[@ref1]^ LBVS methods use various representations of a small molecule, such as fingerprints, chemical topology, 3D shape, pharmacophoric features, physicochemical properties, or some combination of these.^[@ref2]^ These are often captured in a descriptor that is effectively a feature vector representing the molecule. Such descriptors are then compared to that of a known biologically active molecule---a "query"---using a similarity measure or metric, yielding a quantitative score of the similarity of the two molecules. Many similarity measures and metrics, such as Tanimoto, Cosine, Dice, and Tversky, have been reported in the literature (see [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.8b00779/suppl_file/ci8b00779_si_001.pdf), Schema S1).^[@ref3]−[@ref9]^ Consensus scoring combines the results of multiple LBVS searches, typically using data fusion methods, and has been shown to improve the accuracy of virtual screening.^[@ref10],[@ref11]^ LBVS can perform well, especially when finding new hits with the same chemotype as known actives. Chemical topology-based descriptors do not take ligand 3D information into account and tend to be worse at scaffold hopping than 3D approaches. Many popular shape-based ligand-based methods,^[@ref12],[@ref13]^ on the other hand, require an optimal structural superposition before comparing the ligands, which can be slow.

In contrast, structure-based virtual screening (SBVS) methods use information from the 3D structure of the target protein.^[@ref14]−[@ref16]^ Explicit SBVS methods propose a structural hypothesis for how a putative inhibitor binds to a target, by searching for the binding site and optimal binding mode. Candidate docked solutions are ranked by a scoring function, which is based on one of four conceptual approaches: statistical, knowledge-based, force-field-based;^[@ref17]^ or, more recently, machine-learning-based.^[@ref18]^ Despite incremental advances, current SBVS scoring functions tend to correlate poorly with experimental protein--ligand binding affinity.^[@ref17]^ SBVS is a widely used computational method for hit identification, and molecular docking often identifies active submicromolar compounds.^[@ref19]^ The success of homology-model-based SBVS is directly related to the quality of the model,^[@ref20]^ and can be improved by the use of multiple models instead of one.^[@ref21]^ Implicit SBVS methods rely on one or more 3D pharmacophores of active compounds, but they usually require superposition on a query molecule, which can be expensive. Implicit SBVS methods include Discovery Studio's Catalyst and HipHop,^[@ref22]^ LigandScout,^[@ref23]^ LS-Align,^[@ref24]^ PHASE,^[@ref25],[@ref26]^ MOE,^[@ref27]^ ROCS,^[@ref12]^ SHAFTS,^[@ref28]^ and WEGA.^[@ref29]^ Thus, both LBVS and SBVS have limitations restricting their predictive abilities.

Hybrid approaches attempt to improve the performance of virtual screening by combining multiple approaches to overcome the weaknesses of the separate methods.^[@ref30],[@ref31]^ Virtual screening methods can be combined in three ways: (i) in sequence,^[@ref32]^ (ii) in parallel,^[@ref33]^ or (iii) as pure hybrid methodologies.^[@ref34]^ In the sequential approach, different VS methods are used one after another in a workflow or pipeline, with the output of one method serving as the input of another. The idea is to use faster, coarser methods first as filters to reduce the initial very large numbers of molecules to a subset, which are then used in more accurate but time-consuming methods, such as free energy perturbation (FEP).^[@ref35]^ In the parallel approach, several different VS methods are run simultaneously, with the top results of each method being combined and taken to the next phase. In hybrid approaches, such as the one presented in this paper, a single method makes use of information about both the target protein structure and the active ligand(s) to discriminate between actives and inactives.

Most hybrid approaches use information such as shape similarity, volume overlap, or pharmacophoric similarity to one or more known ligands to guide, or filter, the output of a docking program. The use of active ligand information can improve performance; however, a relatively computationally expensive docking run is still required.

We were motivated to develop an alignment-free, hybrid virtual screening method to utilize both ligand and protein information in a computationally efficient manner. Previous work has explored individual aspects of this approach. FuzCav^[@ref36]^ uses a 4833-integer vector to describe a protein--ligand binding site that counts pharmacophoric triplets assigned to the Cα atomic coordinates of residues lining the binding site. While FuzCav is a non-superpositional method, it is mainly used for binding site comparison. The FLAP approach of Baroni et al.^[@ref37]^ describes a common framework for comparing proteins and ligands, based on GRID^[@ref38]−[@ref41]^ molecular interaction fields. Local minima in the interaction fields for the protein of interest are sampled to create four-point pharmacophores, against which conformations of ligands can be searched, on the basis of the GRID atom-type pharmacophores they contain. FLAP enables fast searching but does not utilize knowledge about bound ligands. Both LigandScout^[@ref23]^ and Discovery Studio^[@ref22]^ can be run as hybrid VS methods, but they do not develop descriptors and, furthermore, are dependent on structural superposition, which can be a relatively expensive process. We hypothesized that bound ligands, especially if structurally diverse, contain key information about the energetically most-important interactions that would be useful in guiding the creation of pharmacophore-based database queries.

Therefore, we present "Ligity", a hybrid method that derives interaction features from experimentally determined structures of protein--ligand complexes. These interaction "hot-spots" are mapped to pharmacophoric interaction points, or "PIPs" in the ligand space. Ligity descriptors are built from triangular or chiral tetrahedral combinations of these PIPs. Typically, only a portion of the cognate ligand will be in contact with the protein structure and Ligity considers only these PIPs when constructing a query. Candidate ligands (database compounds) are also converted into Ligity descriptors on the basis of the 3D distribution of pharmacophoric features in their enumerated low-energy conformational ensembles. In this case, all PIPs are used in descriptor construction. Thus, Ligity descriptors for queries will generally be smaller than the Ligity descriptors of database molecules. We have therefore included consideration of the asymmetric Tversky similarity measure to compare descriptors, as this has the useful property that it can detect similarities even if the number of the features in the two descriptors differs significantly. If there are multiple structures for the target protein with different query (cognate) active molecules, Ligity fuses the results of each query. Unlike the hybrid methods in LigandScout and Discovery Studio, Ligity has the advantage that it does not require structural superposition to compare two sets of pharmacophores. Our results show that Ligity performs virtual screening as well as or better than docking methods, but it is much more computationally efficient.

Methods {#sec2}
=======

Ligity is a non-superpositional, knowledge-based, virtual screening method. It uses one or more existing protein--ligand complexes to construct a query. This is used to find biologically active molecules within a large database of small molecule conformational ensembles. An overview of how Ligity works is shown in [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}. The Ligity suite of programs is written in C++ and Python,^[@ref42],[@ref43]^ and it uses the open source cheminformatics toolkit RDKit.^[@ref44]^ When used for virtual screening, the main steps of Ligity are as follows:

![Ligity algorithm. Note that some processes, ionization and generate PIPs, are repeated because they have different implementations depending on whether their input is a 3D protein--ligand complex or a 2D SMILES molecule. Conformer generation uses the protocol published by Ebejer et al.^[@ref49]^](ci8b00779_0001){#fig1}

\(1\) For each 3D protein--ligand complex used as (part of) a query, (a) standardize the ionization state of the protein and cognate ligand in the complex and (b) find protein--ligand interactions based on the maximal distance per interaction type and corresponding SMARTS^[@ref45]^ (SMILES^[@ref46]−[@ref48]^*ar*bitrary *t*arget *s*pecification) definitions for pharmacophoric features, and (c) for each protein--ligand interaction, find the set of PIPs on the cognate ligand.

\(2\) For each molecule in the compound database represented as a SMILES string, (a) standardize the ionization state of the molecule, using the same rules as for the query protein--ligand complex; (b) generate low-energy conformers using the protocol published by Ebejer et al.^[@ref49]^ (Briefly, the number of conformers generated depends on the number of rotatable bonds in the ligand, with 50 for 7 or fewer rotatable bonds, 200 for 8--12 rotatable bonds, and 300 conformers for more flexible ligands. An initial conformer is generated using distance geometry and energy minimized using the UFF force field,^[@ref50]^ and conformers more similar than 0.35 Å RMSD are eliminated); and (c) find the set of PIPs corresponding to each conformer.

\(3\) For the query ligand(s) and compound database PIPs, generate the corresponding Ligity descriptors. These encode the distances and pharmacophoric features between all triangular or chiral tetrahedral combinations of PIPs. The Ligity descriptor is the multidimensional array that stores the counts of the component pharmacophorically labeled triangles or tetrahedra. Each axis in the multidimensional array corresponds to the distance between a pair of PIPs.

\(4\) Calculate the similarity between the descriptors for the query ligand and each conformer in the compound database.

\(5\) Rank the compound database for each protein--ligand query by decreasing similarity.

\(6\) If multiple protein--ligand queries are used, use data fusion to combine the ranked lists into one final list.

Steps 2 and 3, generation of the conformational ensembles and Ligity descriptors for the database compounds, are preprocessing steps that need only be carried out once.

Ligity's Input and Output {#sec2.1}
-------------------------

There are two main inputs to the Ligity algorithm: (1) one or more holo protein--ligand complex structures for the target of interest, the "query", and (2) a database of small molecules in SMILES format to be screened.

When more than one protein--ligand structure is used for the same target, this represents the "information-rich" mode of Ligity. We used the screening-PDB, or sc-PDB,^[@ref51]−[@ref53]^ and its hierarchically clustered binding sites to define these information-rich queries; however, the user is free to select multiple structure queries by other methods. The clustering in sc-PDB is based on both the Enzyme Commission (EC) number and the structural similarity of their binding sites, as defined by SiteAlign.^[@ref54],[@ref55]^ SiteAlign quantifies the topological and pharmacophoric features of binding sites using 1D-fingerprints and attempts to find the best alignment of a target site with the largest query site. Thus, any given cluster of similar binding sites could be used as input for Ligity. It should be emphasized here that Ligity does not require that either the proteins or their holo binding sites should be superimposed, since Ligity is a non-superpositional method.

The input virtual screening library can consist of simply a list of SMILES strings describing the small molecules to be screened. The output of Ligity is a ranked list of all the molecules in the virtual library, ordered by decreasing similarity to the triangular (or chiral tetrahedral) Ligity descriptor(s) of the active cognate ligand(s).

Standardization of the Ionization State {#sec2.2}
---------------------------------------

In order to make chemically meaningful comparisons, we standardize the ionization states of both the protein-bound ligands and the small molecules in the compound database by first adding hydrogens using RDKit and then applying in-house rules (see Table 3.3 in the work by Ebejer^[@ref56]^). These transformations ensure that ionizable groups are consistently charged, e.g., deprotonating COOH into COO^--^. Although this ionization happens in 3D for the protein-bound cognate ligands and in 2D for the virtual screening library, the same chemical transformation rules are applied in both cases. The SMARTS patterns used to treat ionization do not require explicit hydrogens to be added to the protein.

Conformer Generation {#sec2.3}
--------------------

The list of standardized 2D molecules in the virtual screening database are subjected to our RDKit-based^[@ref44]^ conformer generation protocol^[@ref49]^ to generate an ensemble of low-energy 3D atomic coordinates. As described earlier in step 2b, the number of low-energy UFF conformers generated for a given molecule is determined by its number of rotatable bonds, with at most 300 conformers for the most flexible compounds.^[@ref49]^ Normally, Ligity considers all conformers in a molecule's ensemble, but there is also a "high-throughput" mode where only the lowest-energy conformer of the small molecule is used. This makes subsequent steps in the algorithm take a fraction of the time taken for the full conformer set (see "[Computational Efficiency](#sec3.4){ref-type="other"}").

Generation of PIPs {#sec2.4}
------------------

Pharmacophoric models are automatically generated for the standardized 3D protein--ligand query or queries and the conformers for the molecules in the virtual library or database. These pharmacophoric models are represented by a collection of PIPs. These highlight the interesting parts of the molecule or key features necessary for molecular recognition of a ligand by the receptor. Ligity defines six types of pharmacophoric features^[@ref57]^ in the ligands: hydrophobic, aromatic, hydrogen bond donor (HBD), hydrogen bond acceptor (HBA), anion (−), and cation (+) using SMARTS patterns.

The SMARTS patterns representing pharmacophoric features are specified in a feature definition file in RDKit (in `BaseFeatures.fdef`). These were modified to specify the six "PIP types" that are used by Ligity (listed in Table S1 in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.8b00779/suppl_file/ci8b00779_si_001.pdf)). These rules occasionally generate duplicate PIPs with the same PIP type and (*x*, *y*, *z*)-coordinates; in these cases, the duplicates are filtered out to give a set of unique PIPs describing the molecule's shape and pharmacophoric features.

### PIP Generation for the Query Protein--Ligand Complex {#sec2.4.1}

In the case of a query protein--ligand complex, we first identify PIPs in the ligand by applying the SMARTS patterns. PIPs are then discarded if there is no complementary receptor PIP within a defined distance of the ligand PIP. For example, for a hydrogen bond acceptor in the bound ligand, there must a hydrogen bond donor in the protein within 3.9 Å for this ligand feature for the PIP to be retained. This culling of features is determined by the feature pairs and distance criteria shown in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, which are partly assembled from the literature.^[@ref58]−[@ref60]^ Ligity does not distinguish between weak, moderate, and strong hydrogen bonds, which are typically defined using different distance intervals.^[@ref61]^ Also, Ligity does not consider less common and weaker π-interactions, such as π donor--acceptor interactions.^[@ref62]^ PIPs are placed at either the center of an atom or a pseudoatom, as appropriate for the PIP type; e.g., a benzene ring would have an aromatic PIP positioned at the center of the ring.

###### Pharmacophoric Features and Distance Thresholds Used To Define Queries in Ligity

  interacting receptor--ligand PIP pairs   distance threshold (Å)
  ---------------------------------------- ------------------------
  (hydrophobic, hydrophobic)               4.5
  (acceptor, donor)                        3.9
  (cation, anion)                          4.0
  (aromatic, aromatic)                     4.5
  (cation, aromatic)                       4.0

For hydrogen bond acceptor and donor interactions, we also require that the angle between the hydrogen bond donor heavy atom, its bonded hydrogen atom, and the hydrogen bond acceptor atom, should form an angle greater than 90°.

This helps to both prioritize and limit the number of interaction points.

The query protein--ligand complex PIPs are therefore defined as those ligand PIPs that interact with the protein, filtering out parts of the ligand that do not contribute directly to binding to the target, such as solvent-exposed parts of the ligand. These are typically a subset of all the possible PIPs in a ligand. This has a key influence when selecting a similarity measure. An example of PIP generation for a cognate ligand of adenosine deaminase is shown in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.8b00779/suppl_file/ci8b00779_si_001.pdf) (Figure S1).

### PIP Generation for Database Compounds {#sec2.4.2}

PIPs are generated for every conformer of each database compound using the same SMARTS patterns. Database compounds do not go through the culling step, so for every conformer, all PIPs are retained. Thus, the size of the set of PIPs for database compounds tends to be larger than for binding site ligands from the query protein--ligand complex. While every conformer of a given molecule has the same number and types of PIPs, their positions will depend on its atomic coordinates.

Ligity Descriptor Generation {#sec2.5}
----------------------------

The list of PIPs generated either for the query or database compound is used to generate a Ligity descriptor. A descriptor consists of all possible combinations of sets of 3- or 4-PIPs and is assembled as shown in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}.

![Relationship between PIPs and the Ligity descriptor. The lengths of the edges of each triangle are mapped to their corresponding indices in the array of triangle counts. Shown here is a 3-PIP triangle, with features ⟨HBA, HBA, hydrophobic⟩ and edge lengths of ⟨5.8, 6.1, 4.2⟩ mapping onto a Ligity descriptor that uses an edge-length bin size of 1.0 Å. The blue-bin count will be incremented.](ci8b00779_0002){#fig2}

### 3-PIP Combinations {#sec2.5.1}

In the case of 3-PIP combinations, each triplet describes a triangle whose vertices are the PIP types (e.g., ⟨donor, acceptor, acceptor⟩), and whose edges correspond to the distances between those PIPs. Each triangle is then used to populate a 3D "array", mapping each of the three lengths of the triangle's edges to corresponding indices that determine which bin should accumulate the count of that particular PIP triplet combination.

### 4-PIP Combinations {#sec2.5.2}

In the case of 4-PIP combinations, each quadruplet of PIPs describes a tetrahedron whose vertices are the four PIP types (e.g., ⟨donor, acceptor, cation, acceptor⟩) and whose six edges again correspond to the distances between pairs of PIPs. Tetrahedron counts are stored in a six-dimensional array, hereafter referred to as a *hypercube*, using the lengths of each of the six edges to map to the indices corresponding to the appropriate bin that accumulates the counts of PIP types for that specific tetrahedron.

### Ligity Descriptor Bin Sizes {#sec2.5.3}

The location of the bin in the multidimensional array corresponds to the lengths of the edges of the triangle (3-PIP) or tetrahedron (4-PIP) geometries. Each bin stores the number of occurrences of every possible combination of 3-PIP triangle or 4-PIP tetrahedron. The bin size determines the "resolution" of the Ligity descriptor. If the maximum distance between two PIPs of a molecule is 15 Å and a bin size of 1 Å is used, there would be 15 equally sized bins in any dimension of the descriptor. A very fine bin size, e.g., 0.1 Å, would give a descriptor with many bins with most bin counters set to either 0 or 1. On the other hand, a large bin size, of say 30 Å, would result in only one bin with all counters set to the total number of occurrences of each PIP type combination.

In both 3-PIP and 4-PIP combinations, index determinism is ensured by sorting the vertex labels into a canonical order, which ensures that the same 3-PIP triangles or 4-PIP tetrahedra contribute to the same bin counter. For example, with 1 Å sized bins, (⟨HBA, HBD, +⟩, ⟨2.6, 3.7, 3.2⟩) and (⟨HBA, +, HBD⟩, ⟨3.2, 3.7, 2.6⟩) would contribute to the same bin, ⟨+ , HBA, HBD⟩ with indices ⟨3, 2, 3⟩. When a geometry, i.e., a triangle or tetrahedron, contains more than one of the same PIP type (e.g., 3-PIP ⟨HBA, HBD, HBD⟩), the edges for the pairs containing those identical PIP types are sorted by length. This guarantees that identical geometries are also assigned to the same bin counter. For example, using 1 Å sized bins, the 3-PIP triangles {⟨HBA, HBD, HBD⟩, ⟨3.7, 4.2, 2.1⟩} and {⟨HBA, HBD, HBD⟩, ⟨2.1, 4.2, 3.7⟩}, would be counted in the same bin, ⟨HBA, HBD, HBD⟩ with indices ⟨2, 4, 3⟩. Triangles or tetrahedra having any side shorter than 1.5 Å or longer than 15 Å are filtered out. The lower-bound filtering eliminates large numbers of repetitive geometries (such as those found in a six-membered aliphatic rings). We also filter the descriptor to remove 3-PIP and 4-PIP geometries that appear infrequently (e.g., that occur only once) or those that are very common (e.g., \>10 times). PIP geometries that occur frequently in all molecules tend not to be useful for discriminating between actives and decoys.

### Chirality Detection {#sec2.5.4}

A 4-PIP tetrahedron is chiral if all four PIP types are different. We capture this chirality by calculating the chiral volume of the tetrahedron after the four PIPs have been deterministically sorted by their type. [Equation [1](#eq1){ref-type="disp-formula"}](#eq1){ref-type="disp-formula"} gives a positive or negative volume, which distinguishes between the chiral forms of the tetrahedronwhere *a⃗*, *b⃗*, *c⃗*, and *d⃗* are the Cartesian coordinates of the vertices of the PIP tetrahedron. As a performance optimization, we drop the denominator from the volume calculation, as we only need the sign of the result to distinguish chirality.

Similarity Score {#sec2.6}
----------------

The PIP descriptors for the query and for a database compound are used to calculate their similarity. We tested the similarity measures Tanimoto, Dice, Cosine, Common Counts, and Tversky. The similarity score of a database compound is taken to be the highest score from all of its conformers in the conformational ensemble.

The Tversky similarity, *S*~α~β(*A*,*B*), of the Ligity descriptor counts is shown in [Equation [2](#eq2){ref-type="disp-formula"}](#eq2){ref-type="disp-formula"}where *A* is the Ligity descriptor of a protein--ligand query, *B* is the Ligity descriptor of a ligand in the virtual library, *n* is the number of distance bins in the descriptor, and *A*~*i*~ and *B*~*i*~ are the counts of PIP geometries in the *i*th bin. This is the nonbinary implementation of the Tversky index, designed to work with integer vectors as opposed to bit vectors. We tested the Tversky similarity with weights of α = 1, β = 0; α = 0.95, β = 0.05; α = 0.9, β = 0.1; and α = 0.85, β = 0.15. We hypothesized that the asymmetric Tversky measure would work well because, unlike symmetric measures such as the Tanimoto (or Jaccard^[@ref63]^) index, it can be used to emphasize substructural features of a query and would thus help to focus on only those parts of the query ligand that interact with the protein.

Fusion of Ranked Results {#sec2.7}
------------------------

When multiple queries are available, we fuse the results from the different queries into a single list. This is achieved using the maximum similarity (`MAX-SIM`) data fusion method as described by Nasr et al.^[@ref64]^ and is shown in [Equation [3](#eq3){ref-type="disp-formula"}](#eq3){ref-type="disp-formula"}where *S* is the similarity score, *A* is the query vector, *B* is the vector of the ligand in the multiple lists, *B*~*j*~ is the vector of the ligand in list *j*, and \|*B̅*\| is the number of structures being compared. The highest scoring instance of a molecule across all ranking lists is used in a final, single ranking. It should be noted that other fusion methods, such as exponential Tanimoto discriminant, have been reported to do slightly better^[@ref64]^ than `MAX-SIM`, but they are much more complex and require parameters to be fitted.

Performance Measurement {#sec2.8}
-----------------------

All receiver operating characteristic (ROC) curves and area under the ROC curve (AUC) calculations were performed in the R software environment for statistical computing and graphics (version 3.0.0)^[@ref65]^ using the package `ROCR` (version 1.0--4).^[@ref66],[@ref67]^ BEDROC values were calculated using the R package `enrichvs` (version 0.0.5).^[@ref68]^ For BEDROC, we used an α value of 20, as suggested by the authors of this method;^[@ref69]^ this means that "80% of the maximum contribution to the BEDROC comes from the first 8% of the list".

Ligity Parameter Refinement Data Set {#sec2.9}
------------------------------------

There are several parameters in the Ligity method. To identify optimal values we selected three targets that are present in both sc-PDB and DUD-E,^[@ref70]^ which is a widely used benchmark set for evaluating virtual screening methods. DUD-E contains 50 decoy compounds chosen to have similar physicochemical properties but dissimilar 2D topology, for every active compound in the set of 22 886 actives, grouped into 102 diverse target sets, with an average of 224 actives per target. These three targets were adenosine deaminase (ADA), cyclin-dependent kinase 2 (CDK2), and trypsin I (TRY1), as shown in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}. For the CDK2 and TRY1 receptor sets, we randomly selected 100 actives and 100 decoys from the DUD-E sets. For ADA this was not possible, as there are only 93 actives in the DUD-E data set, so we selected all of these and 100 ADA decoys.

###### Targets Used To Identify Optimal Parameter Values and Data Structures for Ligity, along with Their sc-PDB Cluster IDs, PDB IDs, and the Number of Conformers, *n*~*c*~, for the Active and Decoy Sets[a](#tbl2-fn1){ref-type="table-fn"}

                                            PDB ID   *n*~*c*~                 
  ---------------------------------- ------ -------- ---------- ------ ------ ------
  adenosine deaminase (ADA)          0085   1ndv     2e1w       3km8   6002   6394
  cyclin-dependent kinase 2 (CDK2)   1424   1pxm     2bts       2c6m   6839   6697
  trypsin 1 (TRY1)                   1463   1bjv     1o3o       3m35   4647   4956

Three structures of each target were chosen so as to capture the protein flexibility. Each receptor has a randomly selected subset of 100 active and 100 decoy molecules taken from DUD-E, except ADA, which has only 93 actives.

Validation Data Sets {#sec2.10}
--------------------

To benchmark the two modes of Ligity, "HTS mode" and "information-rich mode", we used DUD-E to create two data sets. These consisted of (i) all of the targets in DUD-E and (ii) a randomly selected subset of 10 targets from the DUD-E set that were also present in sc-PDB (2011 release). The focused subset consisted of angiotensin-converting enzyme (ACE), adenosine deaminase (ADA), cyclin-dependent kinase 2 (CDK2), coagulation factor X (FA10), coagulation factor VII (FA7), glucocorticoid receptor (GCR), human immunodeficiency virus type 1 integrase (HIVINT), human immunodeficiency virus type 1 protease (HIVPR), thrombin (THRB), and trypsin I (TRY1). These included the three targets described in the previous section used for Ligity parameter refinement. For each target, we used the sc-PDB cluster of cognate protein--ligand complexes to construct information-rich Ligity queries. We removed the few structures whose ligands caused errors when read by RDKit and then standardized the ionization state of the remaining bound ligands. We also standardized the ionization state and generated conformers for the corresponding actives and decoys of each target taken from DUD-E using the same standardization rules. When present, we removed the cognate ligand in the sc-PDB structure from the corresponding DUD-E actives set, to eliminate any bias in the method. As might be expected, a conformer of the cognate ligand tends to score very highly with the cognate ligand's Ligity descriptor. This effect would be accentuated when using the `MAX-SIM` data fusion method, which takes the highest score for each virtual library molecule across all binding pockets for a target. The final benchmarking data set is shown in [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}. We list the number of sc-PDB protein--ligand structures used as queries, the number of active and decoy compounds, and how many conformers they have.

###### DUD-E Target Datasets Used To Benchmark Ligity, along with Their sc-PDB Clusters, and the Number of Actives and Decoys, with the Number of Conformers, *n*~*c*~, Given in Parentheses

  target                                sc-PDB cluster ID   number of sc-PDB structures   number of actives (*n*~*c*~)   number of decoys (*n*~*c*~)
  ------------------------------------- ------------------- ----------------------------- ------------------------------ -----------------------------
  angiotensin-converting enzyme (ACE)   0132                9                             282 (27 346)                   16 900 (1 307 531)
  adenosine deaminase (ADA)             0085                20                            93 (6 720)                     5 450 (371 990)
  cyclin-dependent kinase 2 (CDK2)      1424                109                           474 (20 480)                   27 850 (1 360 619)
  coagulation factor X (FA10)           0224                81                            537 (39 732)                   28 325 (1 799 269)
  coagulation factor VII (FA7)          0223                15                            114 (9 759)                    6 250 (398 145)
  glucocorticoid receptor (GCR)         0367                7                             258 (8 682)                    14 999 (640 882)
  human immunodeficiency virus                                                                                            
  type 1 integrase (HIVINT)             1167                3                             98 (5 096)                     6 650 (327 474)
  human immunodeficiency virus                                                                                            
  type 1 protease (HIVPR)               0654                166                           535 (27 975)                   35 750 (2 189 091)
  thrombin (THRB)                       0830                113                           461 (34 936)                   27 004 (2 020 395)
  trypsin I (TRY1)                      0850                74                            449 (30 311)                   25 980 (1 706 265)

In order to compare Ligity to another non-superpositional ligand-based virtual screening method, we also tested Oxford Drug Design's proprietary implementation of ElectroShape 4D (version 2.0.2).^[@ref71]^ The virtual screening study was performed by using the 3D cognate ligand as an input to ElectroShape 4D to generate a query descriptor that was used to rank the active and decoy molecules of each receptor. Similar to Ligity, the ionization states of the query molecule and the active and decoy compounds were standardized at physiological pH. This was particularly important for ElectroShape, as it uses partial charges in its similarity computation. All Ligity comparisons were carried out using a single receptor structure, as defined in DUD-E.

Unless otherwise stated, the following computational experiments were carried out using the validation data set described in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}. We tested the effects of (1) using 3-PIP versus 4-PIP combinations for descriptor generation, (2) varying the descriptor length bin sizes used to count similar multi-PIP geometries, (3) using different similarity measures, (4) ranking using either single or `MAX-SIM` fused results, and (5) using the lowest-energy conformer versus multiple conformers for each molecule in a virtual library.

Results and Discussion {#sec3}
======================

We present the results in two parts: the first discusses our investigation to identify the optimal parameters for Ligity. The second part presents the validation of Ligity for virtual screening using DUD-E.^[@ref70]^ The validation was carried out at two levels: (i) using the HTS mode of Ligity on all of DUD-E and (ii) using the information-rich mode of Ligity on a randomly chosen subset of 10 DUD-E targets (ACE, ADA, CDK2, FA10, FA7, GCR, HIVINT, HIVPR, THRB, and TRY1). Of these 10, 3 were selected, ADA, CDK2, and TRY1, for Ligity parameter optimization.

Ligity Parameter Optimization {#sec3.1}
-----------------------------

### 3-PIP versus 4-PIP Descriptors {#sec3.1.1}

We found that, in terms of the method's accuracy as measured by ROC AUC, the 4-PIP descriptors performed marginally better than 3-PIPs on our parameter optimization data set ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.8b00779/suppl_file/ci8b00779_si_001.pdf), Figure S2). However, in terms of storage space, the 3-PIP descriptors are on average 90.75% smaller than the 4-PIP descriptors. This is an important consideration in virtual screening experiments, where it is not uncommon to have millions of molecules to test.

4-PIP descriptors perform better than 3-PIPs for ADA (average AUC improvement of 0.018) and TRY1 (average AUC improvement of 0.020). However, there is a decrease in performance for CDK2, where the 3-PIP descriptor performs better (average 3-PIP AUC improvement over 4-PIP of 0.028). The same pattern is observed in the fused results scoring. It is possible that CDK2's ligands, which tend to be flat, could be better captured by the triangular 3-PIP descriptors. However, given the three-dimensional and chiral nature of ligand binding sites, Ligity uses 4-PIP descriptors by default.

### Descriptor Bin Size {#sec3.1.2}

We evaluated the performance of 4-PIP Ligity descriptors with hypercube bin sizes of 0.5, 1.0, 1.5, and 2.0 Å. The number of query-matching tetrahedra increases with the bin size. The results are shown in Table S2 of the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.8b00779/suppl_file/ci8b00779_si_001.pdf). Results indicate that the optimal bin size may be dependent on the receptor; Ligity performs slightly better for CDK2 with a bin size of 0.5 Å, while it performs better with a bin size of 1.5 Å for ADA and TRY1. It is possible that this observation could be related to the flexibility of the molecules. CDK2 actives and decoys sets are less flexible, as measured by the number of rotatable bonds, than the ADA and TRY1 sets ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.8b00779/suppl_file/ci8b00779_si_001.pdf), Figure S3). Larger, more flexible molecules have many degrees of freedom and a smaller bin size may not capture similarities between the query and database molecules adequately. On the other hand, smaller, less flexible molecules would match a large number of tetrahedrons if large bins are used because many molecules would populate the same bins, increasing the false positive rate and resulting in a decrease in performance. The default value of the bin size in Ligity was chosen to be 1.5 Å.

### Similarity Measures {#sec3.1.3}

Using 4-PIP descriptors and a bin size of 1.5 Å, we investigated the performance of the following similarity measures, Tanimoto, Cosine, Dice, Counts (simple counts of common bins), and Tversky (including different values for α and β). In each case, the ability to rank actives over decoys was assessed by computing the area under the ROC curve for each optimization data set protein. The results are presented in [Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"}.

###### Effect of Different Similarity Measures on Ligity's ROC AUC Performance Using the Parameter Optimizaion Dataset[a](#tbl4-fn1){ref-type="table-fn"}

                  AUC                                                             
  -------- ------ ----------- ----------- ----------- ----------- ------- ------- -----------
  ADA      1ndv   0.791       0.814       0.831       **0.839**   0.799   0.810   0.791
           2e1w   0.904       0.911       0.919       **0.927**   0.909   0.912   0.904
           3km8   **0.796**   0.790       0.784       0.770       0.672   0.714   **0.796**
  mean            0.830       0.838       **0.845**   **0.845**   0.793   0.822   0.830
  fusion          0.893       0.913       0.925       **0.935**   0.912   0.926   0.913
  CDK2     1pxm   **0.636**   0.581       0.541       0.516       0.508   0.530   **0.636**
           2bts   0.700       **0.701**   0.669       0.634       0.539   0.593   0.700
           2c6m   **0.575**   0.553       0.539       0.522       0.513   0.481   **0.575**
  mean            **0.637**   0.611       0.583       0.557       0.520   0.535   **0.637**
  fusion          **0.634**   0.575       0.532       0.508       0.488   0.503   0.576
  TRY1     1bjv   **0.724**   0.511       0.479       0.467       0.412   0.557   **0.724**
           1o3o   **0.671**   0.456       0.394       0.363       0.300   0.417   **0.671**
           3m35   **0.728**   0.709       0.663       0.615       0.483   0.687   **0.728**
  mean            **0.708**   0.559       0.512       0.482       0.398   0.554   **0.708**
  fusion          **0.729**   0.712       0.662       0.611       0.472   0.687   0.728

The best AUC in each row is shown in bold; it can be seen that Tversky with α = 1 and β = 0 performed best. Note that Dice similarity calculations (not shown) gave identical results to Tanimoto. The mean AUC across all three cognate structure queries for each target is shown, as well as the AUC of the `MAX-SIM` fused results over the three individual queries.

The Tanimoto and Dice similarity measures give identical ROC AUCs (see eqs 2 and 3 in Schema S1 in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.8b00779/suppl_file/ci8b00779_si_001.pdf)). These two measures are similar in spirit, the only difference is that Tanimoto is the ratio of the number of common features between the two data structures over the total number of features, while the Dice measure is the ratio of the total number of common features over the average size of the features in the two data structures.

Tversky, with α = 1 and β = 0, and Counts give identical results. This is because Tversky with β = 0 is a special case of Counts, where the number of common features are divided by the number of features in the query, which does not vary, therefore giving the same rankings of actives and decoys. Note that results are different when we consider fused rankings results: this is because when using the Tversky measure, the different protein--ligand queries will normalize the common counts between query and database ligand by a different amount.

[Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"} shows that the different similarity measures perform more consistently for ADA than for CDK2 and TRY1. For CDK2 and TRY1, similarity measures that quantify global similarity between the query and virtual library molecule, such as Tanimoto, perform poorly. This can be explained by considering the number of PIPs in the query compared to the number of database compound PIPs ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.8b00779/suppl_file/ci8b00779_si_001.pdf), Figure S4). The number of query PIPs for CDK2 and TRY1 is smaller than the number of database compound PIPs. In order to capture this asymmetry, we need a similarity measure that captures the substructure nature of the query. By setting the α parameter to 1.0 in the Tversky measure, we place all the importance on the query PIPs (and effectively ignore ligand's PIPs that do not match).

The number of PIPs in the query and the Tversky score AUCs have a moderate Pearson correlation coefficient (*r*) of 0.510, *p* \< 0.05. If we remove the 2c6m query, which seems to be an outlier, from the CDK2 set, the Pearson's correlation coefficient improves to *r* = 0.741, *p* \< 0.05.

### Single Versus Fused Results Rankings {#sec3.1.4}

As expected, [Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"} also shows that consensus scoring using `MAX-SIM` data fusion over the results from multiple queries improves the performance of Ligity. For example, for ADA using Tversky with α = 1 and β = 0, the mean AUC was 0.830, while the fusion AUC was 0.893. Ligity therefore uses `MAX-SIM` data fusion methods across multiple protein--ligand complexes by default.

### Using Lowest Energy Conformer versus Conformational Ensemble {#sec3.1.5}

We were interested in testing two different ligand conformer representations, one where we used only the lowest energy conformer of the molecule and the other where we used a conformational ensemble of up to a maximum of 300 conformers per molecule. Using a single conformer greatly increase the speed and reduces the storage requirements of the method. We tested Ligity using chiral tetrahedral 4-PIPs, a bin size of 1.5 Å, and Tversky similarity with α = 1 and β = 0. Surprisingly, we found that using the lowest-energy conformer rather than the full ensemble had a small effect on the AUC performance of Ligity ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). The average difference in AUC between all nine individual binding site structure queries for ADA, CDK2, and TRY1 is 0.003. For fused results, the average difference in AUC between the full conformer ensemble and the lowest energy conformers is 0.011, with the full conformational ensemble model doing just slightly better.

![Ligity showed little difference when using only the lowest-energy conformer of the active or decoy molecule (left column). Using the lowest-energy conformer when fusing the results also exhibited a minimal effect (right column). The performance of the method using only the lowest-energy conformer is shown with dashed lines, while the performance using the full conformer set is shown with solid lines.](ci8b00779_0003){#fig3}

Since Ligity performed equally well when using only the lowest energy conformer, we decided to test whether the lowest-energy conformers of a molecule scored best when the full conformational ensemble is used. For any molecule, each conformer is assigned a unique integer identifier assigned sequentially to the conformers when sorted by energy. We investigated whether Ligity picked lower conformer identifiers more often than would be expected by random chance. Not all molecules have the same number of conformers in their ensembles, and a random selection is therefore more likely to pick conformer identifier 1 than conformer identifier 300, because every molecule will have at least one conformer but very few will have the maximum possible of 300. Therefore, for the active and decoy sets for ADA, CDK2, and TRY1, we built a theoretical probability function for the selection of conformer identifiers (as identifiers are generated according to the energy rank of the conformer).

The model is described in [Equation [4](#eq4){ref-type="disp-formula"}](#eq4){ref-type="disp-formula"}where *P*(*c*~id~) is the probability of picking a specific conformer with identifier id for all *N* molecules, *N* is the total number of molecules for the receptor (e.g., 93 for ADA actives), and *C*~*i*~ is the conformational ensemble for the *i*th molecule. The probability of picking a conformer identifier that is larger than the conformer ensemble size for that molecule is zero. In our theoretical model, every conformer in an ensemble is equally likely to be picked, regardless of size. (A simplified example is offered in Table S3 of the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.8b00779/suppl_file/ci8b00779_si_001.pdf).)

We compare the Ligity ranking of all conformers of *N* molecules with 1000 randomly generated rankings of the same conformers of these *N* molecules. We generate each of these 1000 random results lists using the probability function in [Equation [4](#eq4){ref-type="disp-formula"}](#eq4){ref-type="disp-formula"}. We then run a Mann--Whitney statistical test for the conformer identifier selection produced by Ligity against each of the 1000 random results lists. In [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"} we show two histograms, of the 1000 resulting *p*-values for the active and decoy sets for ADA. There is a clear preference for Ligity to select lower-energy conformers of actives, where most *p*-values are below our significance level (α) of 0.05 ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}a). In other words, there is a statistically significant difference between the conformer identifiers picked by Ligity for actives and a random set of generated conformer identifiers. We also ran a one-sided test, so we specifically tested for a preference for lower conformer identifier than the random set. For the decoy set ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}b) we saw no significant preference for lower conformer identifiers as opposed to random selection, as there are very few *p*-values smaller than our chosen α (i.e., smaller than 0.05). This differential behavior was observed for all three targets we used while prototyping Ligity, including CDK2 and TRY1.

![Ligity preferentially selects lower-energy conformers for actives but not for decoys: (a) lower conformer identifiers are selected for actives, rather than what one would expect at random, and (b) there is no difference between conformer identifiers selected for decoys and ones selected at random.](ci8b00779_0004){#fig4}

Using only the lowest-energy conformers is sufficient for Ligity to distinguish between actives and decoys. Butler et al.^[@ref72]^ found that bioactive conformations are very close to the global energy minimum: two-thirds of their 99-molecule data set were within 0.5 kcal/mol of the global energy minimum. They used "sophisticated QM-based methods to take into account both the internal energy of the ligand and the solvation effect, and the application of physically meaningful constraints to refine the bioactive conformation" and asserted that strain energies larger than 2 kcal/mol tended to be attributable to structural determination inaccuracies. Others have argued that the strain energy of the bound ligand conformation can be higher than the calculated global minimum for their unbound form, by as much as 5--15 kcal/mol.^[@ref73]−[@ref77]^ Some have claimed that the effect of the bioactive conformation on virtual screening experiments is small.^[@ref78],[@ref79]^ Indeed in some of these studies, starting off with a low-energy conformation instead of the bioactive conformation yielded little difference in enrichment.

The importance of any differences between the bioactive and solution conformations of ligands on their binding affinities remains controversial. In this regard, our findings are consistent with those of Butler et al.

Validating Ligity Using DUD-E {#sec3.2}
-----------------------------

Ligity was validated in two ways: (i) using the HTS mode of Ligity against the entire DUD-E benchmark and (ii) using the information-rich mode against the 7 + 3 targets of [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}. All validation studies used chiral tetrahedral 4-PIP combinations with a bin size of 1.5 Å.

### HTS Mode Ligity {#sec3.2.1}

When running Ligity against the whole of DUD-E, we used only a single known protein--ligand complex to construct our query Ligity descriptor and only the lowest-energy conformer of the full conformer ensemble of an active or decoy was used for screening. This is done for computational efficiency, to enable the large-scale evaluation against the full DUD-E database.

Ligity descriptor generation failed for three of the 102 DUD-E targets. For CAH2, its very small ligand (trifluoromethane sulfonamide in PDB entry 1BCD) only generated three PIPs, and thus, 4-PIP descriptors could not be generated for this query. RDKit was unable to read in the query molecules of AA2AR and PDE5A. Thus, 99 DUD-E targets were used in these validation experiments.

Performance was evaluated for the Tanimoto and Tversky (α = 1 and β = 0) scoring functions using ROC AUC and enrichment factors at 1%. [Table [5](#tbl5){ref-type="other"}](#tbl5){ref-type="other"} shows the performance of Ligity against the 99 Ligity-compatible DUD-E targets in HTS mode. The mean AUC for the ROC curves using the default Tversky index is 0.671 (slightly better than when using Tanimoto index, which has an AUC of 0.622). Ligity in HTS mode performed very well for some targets, with AUCs greater than 0.85 for COMT, ESR1, ESR2, FA7, FPPS, HIVPR, HMDH, MCR, NRAM, RXRA, WEE1, and XIAP. For early enrichment, as measured by the enrichment factor at 1% (EF~1%~), we also found that Tversky performed better than Tanimoto, with an average EF~1%~ of 9.048 versus 5.648, respectively ([Table [5](#tbl5){ref-type="other"}](#tbl5){ref-type="other"}). This indicates good early enrichment behavior using Ligity.

###### Performance of Ligity in HTS Mode against the Ligity-Compatible DUD-E Targets[a](#tbl5-fn1){ref-type="table-fn"}

                          ROC AUC   BEDROC   EF~1%~                    
  -------- ----- -------- --------- -------- -------- ------- -------- --------
  ABL1     182   10 750   0.563     0.473    0.077    0.077   1.653    2.204
  ACE      281   16 877   0.787     0.787    0.336    0.401   12.425   19.525
  ACES     453   26 242   0.634     0.645    0.077    0.155   1.766    5.518
  ADA      93    5 450    0.724     0.660    0.149    0.147   3.251    3.251
  ADA17    532   35 898   0.638     0.728    0.103    0.283   1.317    9.030
  ADRB1    247   15 850   0.523     0.647    0.065    0.129   1.619    5.262
  ADRB2    231   14 999   0.523     0.589    0.052    0.040   1.735    0.000
  AKT1     293   16 450   0.386     0.548    0.039    0.107   2.737    3.080
  AKT2     117   6 900    0.511     0.685    0.140    0.194   8.568    8.568
  ALDR     159   8 988    0.574     0.610    0.202    0.172   10.747   6.322
  AMPC     48    2 845    0.521     0.541    0.049    0.023   0.000    0.000
  ANDR     269   14 349   0.722     0.742    0.194    0.354   4.839    24.938
  AOFB     121   6 875    0.422     0.464    0.045    0.027   1.652    0.000
  BACE1    283   18 100   0.441     0.775    0.017    0.310   0.000    13.062
  BRAF     152   9 950    0.612     0.639    0.208    0.165   12.502   5.264
  CASP3    199   10 694   0.600     0.734    0.068    0.258   0.502    7.031
  CDK2     474   27 838   0.467     0.507    0.021    0.048   0.000    1.055
  COMT     41    3 846    0.789     0.889    0.338    0.665   19.447   58.341
  CP2C9    120   7 449    0.518     0.634    0.058    0.186   1.660    8.299
  CP3A4    170   11 787   0.450     0.493    0.022    0.057   0.000    2.345
  CSF1R    166   12 149   0.526     0.542    0.136    0.152   6.031    7.238
  CXCR4    40    3 405    0.575     0.722    0.217    0.134   12.665   0.000
  DEF      102   5 699    0.732     0.833    0.212    0.379   10.786   15.689
  DHI1     330   19 348   0.481     0.595    0.089    0.062   2.422    1.211
  DPP4     533   40 941   0.586     0.591    0.154    0.157   4.312    3.937
  DRD3     480   34 048   0.484     0.441    0.043    0.046   1.251    0.626
  DYR      231   17 196   0.694     0.758    0.210    0.230   6.504    7.371
  EGFR     542   35 047   0.593     0.491    0.054    0.037   0.922    0.000
  ESR1     383   20 683   0.838     0.861    0.527    0.594   31.281   39.101
  ESR2     367   20 199   0.844     0.870    0.563    0.644   20.130   32.644
  FA10     537   28 324   0.564     0.674    0.058    0.118   0.930    2.232
  FA7      114   6 249    0.762     0.859    0.210    0.332   6.105    8.721
  FABP4    47    2 749    0.786     0.744    0.191    0.276   0.000    10.623
  FAK1     100   5 350    0.642     0.531    0.111    0.065   2.019    0.000
  FGFR1    139   8 698    0.511     0.522    0.036    0.088   0.722    1.445
  FKB1A    111   5 799    0.605     0.751    0.162    0.164   8.122    3.610
  FNTA     592   51 493   0.411     0.625    0.012    0.132   0.000    4.053
  FPPS     85    8 842    0.917     0.985    0.323    0.776   2.360    36.581
  GCR      258   14 998   0.805     0.834    0.244    0.324   3.092    8.116
  GLCM     54    3 790    0.667     0.685    0.182    0.279   1.873    11.240
  GRIA2    158   11 842   0.662     0.684    0.248    0.154   11.392   5.696
  GRIK1    101   6 547    0.656     0.668    0.203    0.102   7.978    1.995
  HDAC2    185   10 300   0.676     0.734    0.187    0.201   4.318    4.318
  HDAC8    170   10 449   0.640     0.819    0.120    0.377   2.946    8.250
  HIVINT   100   6 640    0.390     0.554    0.030    0.116   0.000    3.018
  HIVPR    535   35 724   0.663     0.872    0.072    0.490   0.187    23.898
  HIVRT    338   18 884   0.495     0.475    0.124    0.085   4.443    1.777
  HMDH     170   8 750    0.480     0.906    0.068    0.652   2.358    35.963
  HS90A    88    4 850    0.635     0.506    0.096    0.083   0.000    3.436
  HXK4     92    4 700    0.662     0.803    0.206    0.307   15.192   9.766
  IGF1R    148   9 300    0.502     0.575    0.057    0.189   2.037    14.941
  INHA     43    2 300    0.493     0.575    0.031    0.045   0.000    0.000
  ITAL     138   8 500    0.619     0.465    0.037    0.065   0.000    0.728
  JAK2     107   6 500    0.472     0.475    0.073    0.118   2.807    6.549
  KIF11    116   6 850    0.755     0.781    0.149    0.219   4.289    2.574
  KIT      166   10 449   0.463     0.437    0.045    0.030   0.000    0.000
  KITH     57    2 850    0.649     0.838    0.228    0.709   14.069   47.483
  KPCB     135   8 699    0.753     0.813    0.220    0.338   8.923    12.641
  LCK      419   27 391   0.471     0.437    0.031    0.043   0.000    1.910
  LKHA4    171   9 448    0.718     0.694    0.238    0.150   8.203    1.758
  MAPK2    101   6 148    0.660     0.670    0.174    0.199   5.988    3.992
  MCR      94    5 149    0.816     0.888    0.215    0.454   6.436    19.307
  MET      166   11 249   0.566     0.531    0.130    0.065   6.032    0.603
  MK01     79    4 550    0.518     0.602    0.121    0.206   5.095    3.821
  MK10     104   6 600    0.488     0.489    0.020    0.031   0.962    0.962
  MK14     578   35 847   0.511     0.589    0.040    0.064   0.173    0.519
  MMP13    572   37 199   0.648     0.753    0.134    0.268   2.446    9.957
  MP2K1    121   8 146    0.669     0.569    0.187    0.058   3.293    0.823
  NOS1     98    8 028    0.483     0.451    0.109    0.041   3.071    0.000
  NRAM     98    6 200    0.853     0.859    0.342    0.290   11.221   3.060
  PA2GA    99    5 150    0.793     0.756    0.225    0.153   1.020    3.059
  PARP1    508   30 029   0.635     0.692    0.215    0.231   11.234   7.884
  PGH1     195   10 798   0.645     0.637    0.077    0.100   0.000    2.050
  PGH2     435   23 139   0.716     0.780    0.166    0.291   3.444    9.874
  PLK1     107   6 800    0.658     0.531    0.123    0.048   1.871    0.000
  PNPH     103   6 946    0.575     0.578    0.161    0.181   4.888    8.799
  PPARA    373   19 399   0.783     0.778    0.262    0.280   6.693    7.764
  PPARD    240   12 250   0.547     0.544    0.078    0.098   1.665    2.498
  PPARG    484   25 299   0.515     0.605    0.055    0.118   0.619    4.955
  PRGR     293   15 648   0.740     0.793    0.142    0.318   2.053    14.714
  PTN1     130   7 249    0.398     0.538    0.055    0.090   0.000    3.068
  PUR2     50    2 700    0.851     0.837    0.281    0.255   7.857    1.964
  PYGM     77    3 944    0.403     0.492    0.016    0.137   0.000    3.917
  PYRD     111   6 449    0.682     0.710    0.462    0.413   34.027   16.118
  RENI     104   6 956    0.720     0.789    0.043    0.138   0.000    0.000
  ROCK1    100   6 300    0.347     0.449    0.020    0.084   1.000    4.000
  RXRA     131   6 950    0.788     0.900    0.219    0.596   6.091    27.407
  SAHH     63    3 450    0.874     0.852    0.598    0.542   35.050   27.084
  SRC      524   34 500   0.565     0.477    0.065    0.050   0.382    0.573
  TGFR1    133   8 499    0.609     0.639    0.147    0.154   10.565   4.528
  THB      103   7 450    0.794     0.762    0.238    0.150   10.614   0.965
  THRB     461   27 000   0.605     0.706    0.063    0.166   2.166    5.632
  TRY1     449   25 975   0.711     0.815    0.147    0.280   2.898    6.688
  TRYB1    148   7 650    0.670     0.670    0.153    0.132   3.378    3.378
  TYSY     109   6 745    0.594     0.725    0.071    0.226   0.911    5.468
  UROK     162   9 850    0.525     0.650    0.036    0.120   0.000    1.854
  VGFR2    409   24 948   0.632     0.578    0.083    0.093   1.465    1.465
  WEE1     102   6 150    0.934     0.929    0.789    0.797   59.348   61.294
  XIAP     100   5 150    0.752     0.974    0.190    0.897   8.077    51.490

The mean (and standard deviation in parentheses) values of ROC AUC using Tanimoto is 0.622 (±0.132), while for Tversky it is 0.671 (±0.142); the mean EF~1%~ using Tanimoto is 5.648 (±8.668), while for EF~1%~ using Tversky it is 9.047 (±12.713).

### Information-Rich Mode Ligity {#sec3.2.2}

We would expect Ligity's virtual screening performance to improve with queries built from multiple cognate ligands. To test this, we built Ligity queries using the cognate ligands taken from the protein--ligand complexes in each target's sc-PDB binding site cluster. This represents the information-rich mode of Ligity, by capturing as much information from known actives as possible. We used data fusion on the results by selecting the maximum score across all separate ranking lists, calculating AUC and BEDROC values.

In [Table [6](#tbl6){ref-type="other"}](#tbl6){ref-type="other"} we show the mean AUC for the information-rich mode of Ligity across each individual query run (i.e., each single sc-PDB ligand--protein complex is a separate query) and the corresponding standard deviation (σ). The ROC AUC of the fusion score based on the ranked results of each individual query is also shown, along with the early enrichment BEDROC score for each individual query and for the fused approach. The BEDROC values were calculated using α = 20. Of the 10 receptors tested using Ligity in the information-rich mode, 9 exhibit early enrichment and only CDK2 shows random early enrichment.

###### Ligity Results in Information-Rich Mode Using the DUD-E Validation Subset[a](#tbl6-fn1){ref-type="table-fn"}

  receptor                              mean AUC (±σ)      mean BEDROC (±σ)   fusion AUC   fusion BEDROC
  ------------------------------------- ------------------ ------------------ ------------ ---------------
  angiotensin-converting enzyme (ACE)   0.779 (±0.070)     0.424 (±0.181)     *0.948*      0.776
  adenosine deaminase (ADA)             0.811 (±0.068)     0.302 (±0.102)     *0.894*      0.557
  cyclin-dependent kinase 2 (CDK2)      0.610 (±0.035)     0.081 (±0.047)     *0.643*      0.062
  coagulation factor X (FA10)           0.700 (±0.050)     0.195 (±0.079)     0.716        0.208
  coagulation factor VII (FA7)          0.750 (±0.026)     0.277 (±0.540)     *0.809*      0.270
  glucocorticoid receptor (GCR)         0.790 (±0.094)     0.300 (±0.116)     *0.867*      0.439
  human immunodeficiency virus                                                              
  type 1 integrase (HIVINT)             *0.669* (±0.045)   0.173 (±0.068)     0.637        0.139
  human immunodeficiency virus                                                              
  type 1 protease (HIVPR)               0.874 (±0.018)     0.584 (±0.057)     *0.876*      0.527
  thrombin (THRB)                       0.747 (±0.035)     0.220 (±0.079)     *0.752*      0.185
  trypsin I (TRY1)                      0.725 (±0.060)     0.171 (±0.076)     *0.778*      0.167
                                                                                            
  mean across all receptors             0.745 (±0.050)     0.273 (±0.135)     *0.792*      0.333

It can be seen that Ligity's mean ROC AUC is moderate to excellent across all targets and generally improves when using data fusion. Standard deviation values, σ, are shown in parentheses. The best ROC AUC for each target is in italic.

Ligity's performance across all receptors had mean AUC values ranging from 0.6 to 0.9. Data fusion improved the AUC values by more than 0.05 in half the cases and was only marginally worse than the mean in just one case (HIVINT).

Comparison of Ligity to Existing Methods {#sec3.3}
----------------------------------------

In [Table [7](#tbl7){ref-type="other"}](#tbl7){ref-type="other"}, we compare Ligity's performance to that of two other methods: another non-superpositional, 3D ligand similarity search method, ElectroShape, and the published performance of a protein--ligand docking method, DOCK, for the information-rich data set. For reference, as well as the individual query scores of these PDB structures for Ligity, we also give the data fusion score.

###### ROC AUC Comparison of Methods for a Queries Using Ligity in "Information-Rich Mode"[a](#tbl7-fn1){ref-type="table-fn"})

  DUD-E target   PDB ID   ElectroShape   DOCK          Ligity        Ligity fused
  -------------- -------- -------------- ------------- ------------- --------------
  ACE            3bkl     0.452          0.716         **0.749**     *0.948*
  ADA            2e1w     0.714          0.764         **0.857**     *0.897*
  CDK2           1h00     0.433          ***0.791***   (0.610)       0.644
  FA10           3kl6     0.664          ***0.866***   0.716         0.717
  FA7            1w7x     0.822          ***0.879***   0.762         0.809
  GCR            3bqd     0.521          0.439         **0.807**     *0.869*
  HIVINT         3nf7     0.578          0.642         ***0.717***   0.637
  HIVPR          1xl2     0.495          0.596         **0.836**     *0.877*
  THRB           1ype     0.646          ***0.813***   0.709         0.752
  TRY1           2ayw     0.320          ***0.934***   (0.725)       0.778
                                                                      
  mean AUC                0.565          0.744         **0.749**     *0.793*

For those cases where the specific PDB ID was not present in the corresponding sc-PDB cluster---CDK2 and TRY1---we use all the sc-PDB query descriptors and report the mean AUC in parentheses. Entries with the best AUC among the methods that used only one structure for comparison---DOCK and Ligity---are highlighted in bold. The best AUC for each target is in italic. Ligity with a single active structure does better than all other methods for 4 out of the 10 DUD-E target classes, and 9 times out of 10 Ligity is better than the other non-superpositional method, ElectroShape. Note that when using more than one protein--ligand complex and fusing the results, with the exception of HIVINT, Ligity does even better ("Ligity fused") than when using only one complex ("Ligity").

The AUC values for DOCK in [Table [7](#tbl7){ref-type="other"}](#tbl7){ref-type="other"} were taken from Table S1 of the the Supporting Information reported by Mysinger et al.,^[@ref70]^ where DOCK 3.6 was tested using the same PDB structure (second column of [Table [7](#tbl7){ref-type="other"}](#tbl7){ref-type="other"}) and the same actives and decoys as defined in DUD-E. We did not compare performance with that of 2D fingerprints (e.g., Morgan) because, as the authors of DUD-E state, Daylight^[@ref80]^ fingerprints were used to remove any decoys that were similar to actives, and they warned that this may create an artificially favorable enrichment bias for 2D fingerprinting methods.

Finally, it can be seen that Ligity does slightly better, on average, than the other 3D methods in [Table [7](#tbl7){ref-type="other"}](#tbl7){ref-type="other"}. The results of Ligity with data-fusion had the highest mean AUC of 0.793, followed by Ligity without fusion at 0.749, closely followed by DOCK at 0.744, and then ElectroShape at 0.565. Ligity fused had slightly worse AUCs than DOCK for CDK2, FA10, FA7, THRB, and TRY1 but had significantly better AUCs for ACE, ADA, GCR, and HIVPR. For this data set, the highest ROC AUC is obtained by DOCK for five targets, Ligity with data fusion for four targets, and Ligity without data fusion for one target.

For CDK2, the query receptor for which Ligity does worst (1h00, AUC = 0.61) was not present in the CDK2 binding-site cluster in the sc-PDB release that we used. These sc-PDB clusters contain binding sites that are similar to one another (above a certain threshold) and only contain structures that pass a stringent quality filter. This implies that the 2003-deposited structure for 1h00 might not be similar enough to the sc-PDB binding sites we used as queries. For CDK2, instead we present the average across all the single CDK2 runs, shown in parentheses. A similar case applied for PDB entry 2ayw of TRY1.

ElectroShape tended to perform poorly for this data set, outperforming Ligity for only one target, FA7.

Computational Efficiency {#sec3.4}
------------------------

To determine the computational efficiency of Ligity, we compared it to a popular protein--ligand docking method, AutoDock Vina^[@ref81]^ (refer to [Table [8](#tbl8){ref-type="other"}](#tbl8){ref-type="other"} for speed-up comparison). The benchmarks were carried out using 64-bit GNU/Linux Fedora release 28 running on an Intel Core i7-6700 CPU at 3.40 GHz. A subset of the ADA DUD-E benchmark was constructed using all 93 actives and 100 randomly selected decoys. Ligity requires two steps to run: (i) precalculation of 4-PIP Ligity descriptors for every conformer of each molecule in the database and (ii) comparison of these descriptors with the 4-PIP Ligity descriptor of the query molecule, in this case, ligand FR233623, residue name FR6, in PDB entry 2e1w. Using our C++ implementation of Ligity with 3074 active conformers and 2287 decoy conformers, step i took 9 min 45.9 s, while step ii took 51.4 s. For the docking run, each active and each decoy from the ADA subset was converted into PDBQT-formatted files. The same compounds were flexibly docked using AutoDock Vina instructed to use a single core of the same machine: this took a total of 209 min 46.8 s. Ligity is therefore about 20 times faster than AutoDock Vina. If the Ligity 4-PIP descriptor precalculation is excluded---this only needs to be done once for the database compounds---Ligity is about 245 times faster than AutoDock Vina. In HTS mode, using only the lowest-energy conformation of the actives and decoys, Ligity is about 6800 times faster than docking.

###### Ligity Is about 4--5 Orders of Magnitude Times Faster than Protein--Ligand Docking, Once Its Descriptors Have Been Precalculated for the Virtual Library Being Screened[a](#tbl8-fn1){ref-type="table-fn"}

  method                     mode               CPU time (s)   relative speed-up
  -------------------------- ------------------ -------------- -------------------
  AutoDock Vina              flexible ligand    12586.8        1.0
  Ligity descriptors + VS    information-rich   637.3          19.9
  Ligity descriptors         information-rich   585.9          21.5
  Ligity virtual screening   information-rich   51.4           244.9
  Ligity virtual screening   HTS                1.9            6815.3

This is exemplified by comparing with the already very efficient AutoDock Vina with the ADA target from DUD-E. The "information-rich" mode of Ligity, with multiple conformers per molecule, used a total of 3074 conformers for the 93 actives and 2287 conformers for 100 randomly selected decoys. The "HTS" mode of Ligity used just the lowest-energy conformer in each molecule's conformer ensemble for each active or decoy.

Conclusions {#sec4}
===========

Ligity is a fully automated, non-superpositional, pharmacophore-based method with comparable virtual screening performance to protein--ligand docking methods, while being much faster (some 2--3 orders of magnitude faster than AutoDock Vina). Ligity uses protein--ligand complex structures to build one or more query descriptors based on the geometric arrangement of the pharmacophoric features (PIPs) of the interacting parts of the active ligand(s). Using a subset of DUD-E, we investigated the parameter space of Ligity to maximize enrichment, including using 3-PIP versus 4-PIP pharmacophores, different bin sizes in the descriptor, different similarity measures, data fusion methods to aggregate rankings, and the effect of using the single lowest-energy conformer versus multiple conformers. Optimal results were found using 4-PIP descriptors, a bin size of 1.5 Å, Tversky similarity with α = 1, β = 0, and consensus scoring using `MAX-SIM` data fusion over the results of the multiple bound ligand conformations. These are used as the default settings. Ligity gave slightly better VS performance with ensembles of conformers for the database molecules, but the improved speed when using a single lowest-energy conformer provides a very competitive high-throughput virtual screening "HTS mode". Ligity also performed better in terms of recovery of known actives when multiple ligands bound to the same protein were combined into an "information-rich" Ligity descriptor. It would be interesting to study how sensitive Ligity's results are to the particular choice of protein--ligand structures. This would ideally require a combinatorial examination of all possible sets of protein--ligand binding cavities, and we believe this would be an interesting follow-up study.

Ligity could be used in conjunction with explicit structure-based virtual screening methods, for example by using docked poses of known actives in either apoprotein X-ray structres or homology models. We suspect that, in general, however, the additional structural noise introduced both by subtle variations in the homology models of the proteins and in the docked binding modes of the ligand might reduce the predictive performance of our method.

The novelty of Ligity lies in its descriptor: a three-dimensional array descriptor for all possible triangular 3-PIP feature sets and a six-dimensional hypercube descriptor for all possible chiral tetrahedral 4-PIP combinations. We found the 4-PIP-based Ligity descriptor to perform better than the 3-PIP variant. Furthermore, receptor flexibility can be incorporated by using alternative conformations of the holo protein--ligand complex where there are multiple experimentally resolved structures or from molecular dynamics simulations. Ligand flexibility is captured by ensembles of low-energy conformers. Ligity is also able to distinguish chiral arrangements of pharmacophoric features using our 4-PIP tetrahedral descriptors. The non-superpositional nature of Ligity's descriptors makes it extremely efficient and particularly well-suited for machine-learning applications.

We found that Ligity preferentially picked low-energy conformers for active molecules as the highest scoring conformers on the targets we used to refine the parameters of the method (CDK2, TRY1, and ADA). We showed that this preference is statistically significant for actives but not for decoys. We postulate that, although this is still an open question in the literature, active compounds bind in a relatively low-energy conformation. This finding is consistent with the process of drug discovery. The structure of the active compounds in the DUD-E data sets will often be the result of medicinal chemistry optimization, where optimizing binding affinity is an important goal. One way to achieve this, while low molecular weight (and thus rule-of-5 compliance) is maintained, is to minimize any energy penalty for obtaining the bound conformation. Artificial decoy molecules have undergone no such optimization and, thus, would not be expected to show this effect. This further suggests that this selection effect will only be observed in retrospective virtual screening experiments (using benchmark sets consisting of true positives and putative negatives) but not in prospective ones.

On the basis of the retrospective analysis presented here, we believe that Ligity has potential as a prospective virtual screening method that is able to efficiently and successfully screen databases consisting of millions of molecules.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acs.jcim.8b00779](http://pubs.acs.org/doi/abs/10.1021/acs.jcim.8b00779).Further Ligity experiments, as well as implementation details (Schema S1, Figures S1--S4, and Tables S1--S3) ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.8b00779/suppl_file/ci8b00779_si_001.pdf))
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